RFAI · RF Acquisition Corp II

The thesis

RF Acquisition Corp II is a blank-check shell whose price still turns on how many public shares remain after the Nanyang Biologics merger, and the closing report with final redemptions is the document that settles it. Shareholders approved the deal on 19 August 2026. No closing has been announced as of 29 October 2026.

The shares closed at $31.73 on 28 October 2026, 45.3% below the $58.00 high of 21 August 2026, per split- and dividend-adjusted daily closes. The 14-day relative strength index (RSI, a 0-100 momentum gauge) was 43.3. The three-month gain was still 186.6%. A Benzinga headline on 26 October 2026 said the shares were halted on a circuit breaker to the upside, up 104.2%.

The narrative is maturing but not dead: interest has swung back in short bursts since the August spike, and no new business fact has accompanied the 26 October 2026 move. Roughly the same price range ($31 to $38) has held since early October, with the 26 October 2026 spike fading within two sessions.

Bullish and bearish views on RF Acquisition Corp II

The bull case on RF Acquisition Corp II (RFAI), in brief: Preliminary redemptions imply a very small float. The bear case: No closing has been reported.

Bull case

• Preliminary redemptions imply a very small float. The company's 8-K filed 20 August 2026 reported redemption requests covering 3,956,323 shares, or 98.95% of the 3,998,108 public shares left after the extension redemption. If the final figure holds near that level, few public shares would exist against the retail attention seen again on 26 October 2026.

• The merger vote passed decisively. The business-combination proposal won 6,765,584 votes for and 440,604 against on 19 August 2026 (8-K, Item 5.07). Completion and the Nasdaq listing under the reserved ticker "NYB" remain the open items.

• The 200-day moving average was $17.10 on 26 October 2026, far below the 28 October 2026 close of $31.73.

Bear case

• No closing has been reported. The merger approved on 19 August 2026 had not closed as of 29 October 2026, ten weeks later. The deadline runs to 15 February 2027 through up to six one-month extensions, each needing a $75,000 trust deposit.

• The redemption figure is preliminary. The 20 August 2026 8-K states that final redemptions and trust cash are not set until closing, and holders can withdraw requests. A materially lower final percentage would remove the scarcity argument.

• Price sits below its 50-day average. MarketBeat put the 50-day moving average at $35.54 on 26 October 2026. The 28 October 2026 close of $31.73 is below it, and the RSI of 43.3 is lower than the 52.4 recorded on 15 October 2026.

• Operating results are thin. The amended Form F-4 shows unaudited pro forma revenue of US$43,132 and a net loss of US$8,192,164 for the six months ended 31 March 2026. Nothing in the filings ties the share price to that business.

• Trust value sits far below the price. The trust paid about $11.13 per share to redeeming holders on 12 August 2026. The 28 October 2026 close was $31.73, so the price rests on expected scarcity and not on cash backing.

Price setup

The adjusted close was $31.73 on 28 October 2026, down from $34.00 on 15 October 2026 and $38.33 on 2 October 2026. The closing high was $58.00 on 21 August 2026, and the three-month gain stood at 186.6%.

On 26 October 2026 the shares were halted on an upside circuit breaker and reached an intraday high of $53.42 before last trading at $35.83, per MarketBeat. Nasdaq volatility pauses were also reported on 17 September 2026 (TipRanks) and 13 October 2026 (Tapeboard). The 50-day moving average was $35.54 and the 200-day $17.10 on 26 October 2026.

Crowding evidence: repeated volatility halts, an intraday spike that reversed within the session, and thin volume. No insider sales or new share issuance appear in the filings checked, and no earnings date applies to a shell. MarketBeat lists Weiss Ratings' upgrade to "hold (c-)" on 8 October 2026. No analyst price target has been published.

Catalysts, next 30 days

• ~15 November 2026 (est.): next $75,000 monthly trust extension deposit if closing has not occurred. A further extension would show closing slipping toward 15 February 2027.
• Undated: closing report (Form 8-K or 6-K). It would publish final redemptions and the post-close share count, which settle the scarcity case.
• Undated: Nasdaq listing of the combined company as "NYB". Public-holder and float listing tests are untested at 98.95% preliminary redemptions. A deficiency notice would appear here.

What would change the view

The case breaks if a closing report shows final redemptions materially below the 98.95% preliminary figure, or if Nasdaq denies the listing of the combined company. Either removes the small-float premise on which the price rests.

On price, a daily close below $30 would extend the slide from the $58.00 closing high of 21 August 2026. The 28 October 2026 close of $31.73 is 5.8% above that level. A close back above the 50-day moving average of $35.54 would show buyers returning, though it would not by itself settle the redemption question.

What it trades with

RFAI trades on its own share-count mechanics and attention bursts, not on a sector. No current theme group carries the name. Its units, RFAIU, trade separately, and MarketBeat's 27 October 2026 article noted that a market-gainers mention concerned the units and not the ordinary shares.

Index and sector moves did not explain the two largest swings in the record: the 21 August 2026 jump followed the 8-K on the meeting results, and the 26 October 2026 spike carried no company filing.